Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current earnings are A$47.21 Billion. In 2024 the company made an earning of A$28.56 Billion, an increase over its 2023 earnings that were of A$23.25 Billion. The earnings displayed on this page is the company's Pretax Income.